(18)F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

Response rates of unselected non–small cell lung cancer (NSCLC) patients to the epidermal growth factor receptor inhibitor erlotinib are low and range from 10% to 20%. Early response assessments are needed to avoid costs and side effects of inefficient treatments. Here we determined whether early ch...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Nucl Med
Hoofdauteurs: Benz, Matthias R., Herrmann, Ken, Walter, Franziska, Garon, Edward B., Reckamp, Karen L., Figlin, Robert, Phelps, Michael E., Weber, Wolfgang A., Czernin, Johannes, Allen-Auerbach, Martin S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2011
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021512/
https://ncbi.nlm.nih.gov/pubmed/22045706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.111.095257
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items